In addition, MUC1-C has been found to be a excellent therapeutic target for breast cancer, and it participates in many classical pathways of cancer, including the MEK/ERK pathway [60], Wnt/β-catenin pathway [61], STAT/NF-κB pathway [62], and the PI3K/AKT pathway [28, 63–66]. This evidence concerns the gene NFKB1 and breast carcinoma.